“…The authors identified 1245 and 21,243 reports listing gastroparesis or dyspepsia, respectively; the demographics of these reports mirrored published epidemiologic factors with a female predominance and mean age in the sixth decade [1,8]. It is unclear whether FAERS reports associated with treatment of dyspepsia refer to the syndrome of functional dyspepsia or with isolated dyspepsia, a symptom commonly accompanying gastroesophageal reflux disease [1,3]. This distinction remains important globally since treatment of functional dyspepsia can include the use of the few prokinetic agents available for functional dyspepsia, including, metoclopramide, a drug that is not generally recommended [12].…”